Live Breaking News & Updates on Nasdaq Arqt

Stay updated with breaking news from Nasdaq arqt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $26.56 Consensus Price Target from Analysts

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among […] ....

Arcutis Biotherapeutics , Masaru Matsuda , Needham Company , Tejara Capital Ltd , Securities Exchange Commission , Arcutis Biotherapeutics Inc , China Universal Asset Management Co , Deutsche Bank , Goldman Sachs Group , Get Free Report , Exchange Commission , Universal Asset Management , Capital Ltd , Get Free , Nasdaq Arqt ,

Arcutis Biotherapeutics Reports Inducement Grants Under

WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company. ....

Derek Cole , Amanda Sheldon , Latha Vairavan , Compensation Committee Of Arcuti Board Directors , Arcutis Biotherapeutics Inc , Investor Relations Advisory Solutions , Exchange Commission , Head Of Corporate Communications , Compensation Committee , Arcuti Board , Nasdaq Listing Rule , Private Securities Litigation Reform Act , Vice President , Relations Advisory , Nasdaq Arqt , Arcutis Biotherapeutics ,

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4.6%

Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) were down 4.6% during trading on Thursday . The stock traded as low as $10.17 and last traded at $10.30. Approximately 1,029,580 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 5,305,673 shares. The stock had previously closed […] ....

Hong Kong , Masaru Matsuda , Arcutis Biotherapeutics , Cantor Fitzgerald , Securities Exchange Commission , Hong Kong Ltd , China Universal Asset Management Co , Arcutis Biotherapeutics Company Profile , Victory Capital Management Inc , Cape Investment Advisory Inc , Arcutis Biotherapeutics Inc , Needham Company , Goldman Sachs Group , Get Free Report , Exchange Commission , Investment Advisory , Kong Ltd , Capital Management , China Universal Asset Management , Universal Asset Management , Nasdaq Arqt ,

Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 7.7%

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report)’s stock price was down 7.7% during mid-day trading on Monday . The company traded as low as $10.06 and last traded at $10.29. Approximately 1,248,266 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 5,378,077 shares. The stock had previously […] ....

Hong Kong , Arcutis Biotherapeutics , Masaru Matsuda , Group Plc , Morgan Stanley , Arcutis Biotherapeutics Company Profile , Arcutis Biotherapeutics Inc , Goldman Sachs Group , Hong Kong Ltd , Jpmorgan Chase Co , Needham Company , Dimensional Fund Advisors , Get Free Report , Kong Ltd , General Group Plc , Fund Advisors , Nasdaq Arqt ,

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement . ....

San Diego , United States , Amanda Sheldon , Latha Vairavan , Derek Cole , Drug Administration , Exchange Commission , Head Of Corporate Communications , Arcutis Biotherapeutics Inc , American Academy Of Dermatology , Eczema Area , Severity Index , Worst Itch Numeric Scale , Investigator Global Assessment , Atopic Dermatitis , American Academy , Prescription Drug User Fee Act , Private Securities Litigation Reform Act , Vice President , Nasdaq Arqt , Arcutis Biotherapeutics , Roflumilast Cream , Atopic Dermatitis ,